ESR1 and neoplasm: Given that the inhibition of EDI3 can reduce in vitro cell viability and in vivo tumor growth in ER-/HER2+ cells resistant to HER2-targeted therapies, EDI3 may represent a potential novel therapeutic target worthy of further exploration [92].